Advertisement

Chemotherapy for Diffuse Low-Grade Gliomas

  • Luc TaillandierEmail author
Chapter

Abstract

Diffuse low-grade gliomas are rare tumors. Therapeutic strategies have dramatically changed in recent years, thanks to observational data, insight of some authors, retrospective studies, and, incidentally, results of few phase III and II trials. Surgery has become the cornerstone of the treatment. Radiotherapy, because of its potential delayed neurotoxicity and the equivalent results in terms of survival whatever the timing of the treatment (early or late), is increasingly offered to patients with unresectable tumors (or tumor that cannot be reoperated) and in case of progression after chemotherapy. Chemotherapy, subject of this chapter, has shown clinical benefits regarding tumor progression for nonsurgical patients, before or after radiotherapy: initial chemosensitivity almost constant, improvement of epilepsy and thus of cognition, and preservation of quality of life (despite a possible transient alteration). Its articulation with surgery has been more recently discussed by allowing, thanks to tumor shrinkage, subtotal or total resection (whose impact on anaplastic transformation and survival has been demonstrated), in addition to potential effects on cerebral plasticity. It remains to show the direct or indirect impact on survival, to refine its risk-benefit ratio, especially in the context of prolonged treatment with temozolomide, and to develop further research from a neurological (impact on plasticity) and oncological (involved molecular pathways, identifying new therapeutic targets) points of view.

Keywords

Diffuse low-grade gliomas WHO grade II gliomas Chemotherapy Epilepsy Quality of life Survival 

References

  1. 1.
    Whittle IR. The dilemma of low grade glioma. J Neurol Neurosurg Psychiatry. 2004;75 Suppl 2:ii31–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Duffau H. The challenge to remove diffuse low-grade gliomas while preserving brain functions. Acta Neurochir (Wien). 2012;154:569–74.CrossRefGoogle Scholar
  3. 3.
    Sanai N, Chang S, Berger MS. Low-grade gliomas in adults. J Neurosurg. 2011;115:948–65.PubMedCrossRefGoogle Scholar
  4. 4.
    Douw L, Klein M, Fagel SS, van den Heuvel J, Taphoorn MJ, Aaronson NK, Postma TJ, Vandertop WP, Mooij JJ, Boerman RH, Beute GN, Sluimer JD, Slotman BJ, Reijneveld JC, Heimans JJ. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 2009;8:810–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Eyre HJ, Crowley JJ, Townsend JJ, Eltringham JR, Morantz RA, Schulman SF, Quagliana JM, Al-Sarraf M. A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a southwest Oncology Group Study. J Neurosurg. 1993;78:909–14.PubMedCrossRefGoogle Scholar
  6. 6.
    Cairncross JG, Macdonald DR. Oligodendroglioma: a new chemosensitive tumor. J Clin Oncol. 1990;8:2090–1.PubMedGoogle Scholar
  7. 7.
    Macdonald DR, Gaspar LE, Cairncross JG. Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol. 1990;27:573–4.PubMedCrossRefGoogle Scholar
  8. 8.
    Mason WP, Krol GS, DeAngelis LM. Low grade oligodendroglioma responds to chemotherapy. Neurology. 1996;46:203–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Soffietti R, Ruda R, Bradac GB, Schiffer D. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery. 1998;43:1066–73.PubMedCrossRefGoogle Scholar
  10. 10.
    Ducray F. Chemotherapy for diffuse low-grade gliomas in adults. Rev Neurol (Paris). 2011;167:673–9.CrossRefGoogle Scholar
  11. 11.
    Pouratian N, Schiff D. Management of low-grade glioma. Curr Neurol Neurosci Rep. 2010;10:224–31.PubMedCrossRefGoogle Scholar
  12. 12.
    Soffietti R, Baumert BG, Bello L, von Deimling A, Duffau H, Frénay M, Grisold W, Grant R, Graus F, Hoang-Xuan K, Klein M, Melin B, Rees J, Siegal T, Smits A, Stupp R, Wick W, European Federation of Neurological Societies. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol. 2010;17:1124–33.PubMedCrossRefGoogle Scholar
  13. 13.
    Gutin PH, Wilson CB, Kumar AR, Boldrey EB, Levin V, Powell M, Enot KJ. Phase II study of procarbazine, CCNU, and vincristine combination chemotherapy in the treatment of malignant brain tumors. Cancer. 1975;35:1398–404.PubMedCrossRefGoogle Scholar
  14. 14.
    Levin VA, Edwards MS, Wright DC, Seager ML, Schimberg TP, Townsend JJ, Wilson CB. Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep. 1980;64:237–44.PubMedGoogle Scholar
  15. 15.
    Levin VA, Wara WM, Davis RL, Vestnys P, Resser KJ, Yatsko K, Nutik S, Gutin PH, Wilson CB. Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. J Neurosurg. 1985;63:218–23.PubMedCrossRefGoogle Scholar
  16. 16.
    Mohile NA, Forsyth P, Stewart D, Raizer JJ, Paleologos N, Kewalramani T, Louis DN, Cairncross JG, Abrey LE. A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis. J Neurooncol. 2008;89:187–93.PubMedCrossRefGoogle Scholar
  17. 17.
    Lashkari HP, Saso S, Moreno L, Athanasiou T, Zacharoulis S. Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity. J Neurooncol. 2011;105:135–47.PubMedCrossRefGoogle Scholar
  18. 18.
    Macdonald DR, Cascino TL, Schold Jr SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277–80.PubMedGoogle Scholar
  19. 19.
    Brada M, Viviers L, Abson C, Hines F, Britton J, Ashley S, Sardell S, Traish D, Gonsalves A, Wilkins P, Westbury C. Phase II study of primary temozolomide chemotherapy in patients with WHO II grade gliomas. Ann Oncol. 2003;14:1715–21.PubMedCrossRefGoogle Scholar
  20. 20.
    Buckner JC, Gesme Jr D, O’Fallon JR, Hammack JE, Stafford S, Brown PD, Hawkins R, Scheithauer BW, Erickson BJ, Levitt R, Shaw EG, Jenkins R. Phase II trial of procarbazine, lomustine and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol. 2003;21:251–5.PubMedCrossRefGoogle Scholar
  21. 21.
    Pace A, Vidiri A, Galie E, Carosi M, Telera S, Cianciulli AM, Canalini P, Giannarelli D, Jandolo B, Carapella CM. Temozolomide chemotherapy for progressive low-grade glioma :clinical benefits and radiological response. Ann Oncol. 2003;14:1722–6.PubMedCrossRefGoogle Scholar
  22. 22.
    van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJ, Jaeckle K, Junck L, Armstrong T, Choucair A, Waldman AD, Gorlia T, Chamberlain M, Baumert BG, Vogelbaum MA, Macdonald DR, Reardon DA, Wen PY, Chang SM, Jacobs AH. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011;12:583–93.PubMedCrossRefGoogle Scholar
  23. 23.
    Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune J, Polivka M, Crinière E, Marie Y, Mokhtari K, Carpentier AF, Laigle F, Simon JM, Cornu P, Broët P, Sanson M, Delattre JY. Temozolomide as initial treatment for adults with low-grade ­oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol. 2004;22(15):3133–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Ricard D, Kaloshi G, Amiel-Benouaich A, Lejeune J, Marie Y, Mandonnet E, Kujas M, Mokhtari K, Taillibert S, Laigle-Donadey F, Carpentier AF, Omuro A, Capelle L, Duffau H, Cornu P, Guillevin R, Sanson M, Hoang-Xuan K, Delattre JY. Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann Neurol. 2007;61:484–90.PubMedCrossRefGoogle Scholar
  25. 25.
    Mandonnet E, Delattre JY, Tanguy ML, Swanson KR, Carpentier AF, Duffau H, Cornu P, Van Effenterre R, Alvord Jr EC, Capelle L. Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol. 2003;53:524–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Blonski M, Taillandier L, Herbet G, Maldonado IL, Beauchesne P, Fabbro M, Campello C, Gozé C, Rigau V, Moritz-Gasser S, Kerr C, Rudà R, Soffietti R, Bauchet L, Duffau H. Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life. J Neurooncol. 2012;106:353–66.PubMedCrossRefGoogle Scholar
  27. 27.
    Duffau H, Capelle L, Lopes M, Bitar A, Sichez JP, van Effenterre R. Medically intractable epilepsy from insular low-grade gliomas: improvement after an extended lesionectomy. Acta Neurochir (Wien). 2002;144:563–72.CrossRefGoogle Scholar
  28. 28.
    Stockhammer F, Misch M, Helms HJ, Lengler U, Prall F, von Deimling A, Hartmann C. IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom. Seizure. 2012;21:194–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Kurzwelly D, Herrlinger U, Simon M. Seizures in patients with low-grade gliomas – incidence, pathogenesis, surgical management, and pharmacotherapy. Adv Tech Stand Neurosurg. 2010;35:81–111.PubMedCrossRefGoogle Scholar
  30. 30.
    Hu A, Xu Z, Kim RY, Nguyen A, Lee JW, Kesari S. Seizure control: a secondary benefit of chemotherapeutic temozolomide in brain cancer patients. Epilepsy Res. 2011;95:270–2.PubMedCrossRefGoogle Scholar
  31. 31.
    Ochsenbein AF, Schubert AD, Vassella E, Mariani L. Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas. J Neurooncol. 2011;103:343–51.PubMedCrossRefGoogle Scholar
  32. 32.
    Sherman JH, Moldovan K, Yeoh HK, Starke RM, Pouratian N, Shaffrey ME, Schiff D. Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas. J Neurosurg. 2011;114:1617–21.PubMedCrossRefGoogle Scholar
  33. 33.
    Taillandier L, Duffau H. Epilepsy and insular grade II gliomas: an interdisciplinary point of view from a ­retrospective monocentric series of 46 cases. Neurosurg Focus. 2009;27(2):E8.PubMedCrossRefGoogle Scholar
  34. 34.
    Maschio M, Dinapoli L, Mingoia M, Sperati F, Pace A, Pompili A, Carapella CM, Vidiri A, Muti P. Lacosamide as add-on in brain tumor-related epilepsy: preliminary report on efficacy and tolerability. J Neurol. 2011;258:2100–4.PubMedCrossRefGoogle Scholar
  35. 35.
    Vecht CJ, Wilms EB. Seizures in low- and high-grade gliomas: current management and future outlook. Expert Rev Anticancer Ther. 2010;10:663–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, Brandes AA, Bogdahn U, Macdonald DR, Forsyth P, Rossetti AO, Lacombe D, Mirimanoff RO, Vecht CJ, Stupp R. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology. 2011;77:1156–64.PubMedCrossRefGoogle Scholar
  37. 37.
    Moritz-Gasser S, Herbet G, Maldonado IL, Duffau H. Lexical access speed is significantly correlated with the return to professional activities after awake surgery for low-grade gliomas. J Neurooncol. 2012;107:633–41.PubMedCrossRefGoogle Scholar
  38. 38.
    Aaronson NK, Taphoorn MJ, Heimans JJ, Postma TJ, Gundy CM, Beute GN, Slotman BJ, Klein M. Compromised health-related quality of life in patients with low-grade glioma. J Clin Oncol. 2011;29:4430–5.PubMedCrossRefGoogle Scholar
  39. 39.
    Correa DD, DeAngelis LM, Shi W, Thaler HT, Lin M, Abrey LE. Cognitive functions in low-grade gliomas: disease and treatment effects. J Neurooncol. 2007;81:175–84.PubMedCrossRefGoogle Scholar
  40. 40.
    Correa DD, Shi W, Thaler HT, Cheung AM, DeAngelis LM, Abrey LE. Longitudinal cognitive follow-up in low grade gliomas. J Neurooncol. 2008;86:321–7.PubMedCrossRefGoogle Scholar
  41. 41.
    Taphoorn MJ, van den Bent MJ, Mauer ME, Coens C, Delattre JY, Brandes AA, Sillevis Smitt PA, Bernsen HJ, Frénay M, Tijssen CC, Lacombe D, Allgeier A, Bottomley A, European Organisation for Research and Treatment of Cancer. Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. J Clin Oncol. 2007;25:5723–30.PubMedCrossRefGoogle Scholar
  42. 42.
    Liu R, Solheim K, Polley MY, Lamborn KR, Page M, Fedoroff A, Rabbitt J, Butowski N, Prados M, Chang SM. Quality of life in low-grade glioma patients receiving temozolomide. Neuro Oncol. 2009;11:59–68.PubMedCrossRefGoogle Scholar
  43. 43.
    Chang EF, Clark A, Smith JS, Polley MY, Chang SM, Barbaro NM, Parsa AT, McDermott MW, Berger MS. Functional mapping-guided resection of low-grade gliomas in eloquent areas of the brain: improvement of long-term survival. J Neurosurg. 2011;114:566–73.PubMedCrossRefGoogle Scholar
  44. 44.
    Prabhu VC, Khaldi A, Barton KP, Melian E, Schneck MJ, Primeau MJ, Lee JM. Management of diffuse low-grade cerebral gliomas. Neurol Clin. 2010;28:1037–59.PubMedCrossRefGoogle Scholar
  45. 45.
    Greene MH, Boice Jr JD, Greer BE, Blessing JA, Dembo AJ. Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized clinical trials. N Engl J Med. 1982;307:1416–21.PubMedCrossRefGoogle Scholar
  46. 46.
    Boice Jr JD, Greene MH, Killen Jr JY, Ellenberg SS, Keehn RJ, McFadden E, Chen TT, Fraumeni Jr JF. Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). N Engl J Med. 1983;309:1079–84.PubMedCrossRefGoogle Scholar
  47. 47.
    Greene MH, Boice Jr JD, Strike TA. Carmustine as a cause of acute nonlymphocytic leukemia. N Engl J Med. 1985;313:579.PubMedCrossRefGoogle Scholar
  48. 48.
    Baehring JM, Marks PW. Treatment-related myelodysplasia in patients with primary brain tumors. Neuro Oncol. 2012;14:529–40.PubMedCrossRefGoogle Scholar
  49. 49.
    Duffner PK, Krischer JP, Horowitz ME, et al. Second malignancies in young children with primary brain tumors following treatment with pro- longed postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group study. Ann Neurol. 1998;44(3):313–6.PubMedCrossRefGoogle Scholar
  50. 50.
    Perry JR, Brown MT, Gockerman JP. Acute leukemia following treatment of malignant glioma. J Neurooncol. 1998;40:39–46.PubMedCrossRefGoogle Scholar
  51. 51.
    Khasraw M, Bell D, Wheeler H. Long-term use of temozolomide: could you use temozolomide safely for life in gliomas? J Clin Neurosci. 2009;16:854–5.PubMedCrossRefGoogle Scholar
  52. 52.
    Natelson EA, Pyatt D. Temozolomide-induced myelodysplasia. Adv Hematol Vol. 2010;Article ID 760402:5.Google Scholar
  53. 53.
    Harel S, Fermé C, Poirot C. Management of fertility in patients treated for Hodgkin’s lymphoma. Haematologica. 2011;96:1692–9.PubMedCrossRefGoogle Scholar
  54. 54.
    Dobrzyńska MM, Czajka U, Słowikowska MG. Reproductive effects after exposure of male mice to vincristine and to a combination of X-rays and vincristine. Reprod Fertil Dev. 2005;17:759–67.PubMedCrossRefGoogle Scholar
  55. 55.
    Sitbon Sitruk L, Sanson M, Prades M, Lefebvre G, Schubert B, Poirot C. Unknown gonadotoxicity chemotherapy and preservation of fertility: example of Temozolomide. Gynecol Obstet Fertil. 2010;38:660–2.PubMedCrossRefGoogle Scholar
  56. 56.
    Palmieri C, Brock C, Newlands ES. Maintenance of fertility following treatment with temozolomide for a high grade astrocytoma. J Neurooncol. 2005;73:185.PubMedCrossRefGoogle Scholar
  57. 57.
    Sioka C, Kyritsis AP. Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol. 2009;63:761–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Mertens AC, Yasui Y, Liu Y, Stovall M, Hutchinson R, Ginsberg J, Sklar C, Robison LL, Childhood Cancer Survivor Study. Pulmonary complications in survivors of childhood and adolescent cancer. A report from the Childhood Cancer Survivor Study. Cancer. 2002;95:2431–41.PubMedCrossRefGoogle Scholar
  59. 59.
    Sarganas G, Orzechowski HD, Klimpel A, Thomae M, Kauffmann W, Herbst H, Bronder E, Garbe E. Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system. Neuro Oncol. 2012;14:541–6.PubMedCrossRefGoogle Scholar
  60. 60.
    Mandonnet E, Duffau H, Bauchet L. A new tool for grade II glioma studies: plotting cumulative time with quality of life versus time to malignant transformation. J Neurooncol. 2012;106:213–5.PubMedCrossRefGoogle Scholar
  61. 61.
    Klein M. Health-related quality of life aspects in patients with low-grade glioma. Adv Tech Stand Neurosurg. 2010;35:213–35.PubMedCrossRefGoogle Scholar
  62. 62.
    Erickson BJ, Wood CP, Kaufmann TJ, Patriarche JW, Mandrekar J. Optimal presentation modes for detecting brain tumor progression. AJNR Am J Neuroradiol. 2011;32:1652–57.PubMedCrossRefGoogle Scholar
  63. 63.
    Mandonnet E, Pallud J, Clatz O, Taillandier L, Konukoglu E, Duffau H, Capelle L. Computational modeling of the WHO grade II glioma dynamics: principles and applications to management paradigm. Neurosurg Rev. 2008;31:263–9.PubMedCrossRefGoogle Scholar
  64. 64.
    Nelson SJ. Assessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI. NMR Biomed. 2011;24:734–49.PubMedGoogle Scholar
  65. 65.
    Guillevin R, Menuel C, Taillibert S, Capelle L, Costalat R, Abud L, Habas C, De Marco G, Hoang-Xuan K, Chiras J, Vallée JN. Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy. Br J Cancer. 2011;104:1854–61.PubMedCrossRefGoogle Scholar
  66. 66.
    Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, Afra D, Cornu P, Bolla M, Vecht C, Karim AB, European Organization for Research and Treatment of Cancer Brain Tumor Cooperative Group; European Organization for Research and Treatment of Cancer Radiotherapy Cooperative Group. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002;20:2076–84.PubMedCrossRefGoogle Scholar
  67. 67.
    Chang EF, Clark A, Jensen RL, Bernstein M, Guha A, Carrabba G, Mukhopadhyay D, Kim W, Liau LM, Chang SM, Smith JS, Berger MS, McDermott MW. Multiinstitutional validation of the University of California at San Francisco Low-Grade Glioma Prognostic Scoring System. Clinical article. J Neurosurg. 2009;111:203–10.PubMedCrossRefGoogle Scholar
  68. 68.
    Daniels TB, Brown PD, Felten SJ, Wu W, Buckner JC, Arusell RM, Curran WJ, Abrams RA, Schiff D, Shaw EG. Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51. Int J Radiat Oncol Biol Phys. 2011;81:218–24.PubMedCrossRefGoogle Scholar
  69. 69.
    Vöglein J, Tüttenberg J, Weimer M, Gerigk L, Kauczor HU, Essig M, Weber MA. Treatment monitoring in gliomas: comparison of dynamic susceptibility-weighted contrast-enhanced and spectroscopic MRI techniques for identifying treatment failure. Invest Radiol. 2011;46:390–400.PubMedCrossRefGoogle Scholar
  70. 70.
    Murphy PS, Viviers L, Abson C, Rowland IJ, Brada M, Leach MO, Dzik-Jurasz AS. Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy. Br J Cancer. 2004;90:781–6.PubMedCrossRefGoogle Scholar
  71. 71.
    Kim YH, Nobusawa S, Mittelbronn M, Paulus W, Brokinkel B, Keyvani K, Sure U, Wrede K, Nakazato Y, Tanaka Y, Vital A, Mariani L, Stawski R, Watanabe T, De Girolami U, Kleihues P, Ohgaki H. Molecular classification of low-grade diffuse gliomas. Am J Pathol. 2010;177:2708–14.PubMedCrossRefGoogle Scholar
  72. 72.
    Figarella-Branger D, Maues de Paula A, Colin C, Bouvier C. Histomolecular classification of adult diffuse gliomas: the diagnostic value of immunohistochemical markers. Rev Neurol (Paris). 2011;167:683–90.CrossRefGoogle Scholar
  73. 73.
    Pollo B. Neuropathological diagnosis of brain tumours. Neurol Sci. 2011;32 Suppl 2:S209–11.PubMedCrossRefGoogle Scholar
  74. 74.
    Hartmann C, Hentschel B, Tatagiba M, Schramm J, Schnell O, Seidel C, Stein R, Reifenberger G, Pietsch T, von Deimling A, Loeffler M, Weller M, for the German Glioma Network. Molecular markers in low-grade gliomas: predictive or prognostic? Clin Cancer Res. 2011;17:4588–99.PubMedCrossRefGoogle Scholar
  75. 75.
    Iwadate Y, Matsutani T, Hasegawa Y, Shinozaki N, Higuchi Y, Saeki N. Favorable long-term outcome of low-grade oligodendrogliomas irrespective of 1p/19q status when treated without radiotherapy. J Neurooncol. 2011;102:443–9.PubMedCrossRefGoogle Scholar
  76. 76.
    Kaloshi G, Benouaich-Amiel A, Diakite F, Taillibert S, Lejeune J, Laigle-Donadey F, Renard MA, Iraqi W, Idbaih A, Paris S, Capelle L, Duffau H, Cornu P, Simon JM, Mokhtari K, Polivka M, Omuro A, Carpentier A, Sanson M, Delattre JY, Hoang-Xuan K. Temozolomide for low grade gliomas: predictive impact of 1p/19q on response and outcome. Neurology. 2007;68:1831–6.PubMedCrossRefGoogle Scholar
  77. 77.
    Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, Paris S, Boisselier B, Idbaih A, Laigle-Donadey F, Hoang-Xuan K, Sanson M, Delattre JY. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology. 2010;75:1560–6.PubMedCrossRefGoogle Scholar
  78. 78.
    Taal W, Dubbink HJ, Zonnenberg CB, Zonnenberg BA, Postma TJ, Gijtenbeek JM, Boogerd W, Groenendijk FH, Kros JM, Kouwenhoven MC, van Marion R, van Heuvel I, van der Holt B, Bromberg JE, Sillevis Smitt PA, Dinjens WN, van den Bent MJ, Dutch Society for Neuro-Oncology. First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response. Neuro Oncol. 2011;13:235–41.PubMedCrossRefGoogle Scholar
  79. 79.
    Musat E, Roelofs E, Bar-Deroma R, Fenton P, Gulyban A, Collette L, Stupp R, Weber DC, Bernard Davis J, Aird E, Baumert BG. Dummy run and conformity indices in the ongoing EORTC low-grade glioma trial 22033–26033: First evaluation of quality of radiotherapy planning. Radiother Oncol. 2010;95:218–24.PubMedCrossRefGoogle Scholar
  80. 80.
    Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Provenzale JM, McLendon RE, Gururangan S, Bigner DD, Herndon 2nd JE, Avgeropoulos N, Finlay J, Tourt-Uhlig S, Affronti ML, Evans B, Stafford-Fox V, Zaknoen S, Friedman HS. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol. 2003;21:646–51.PubMedCrossRefGoogle Scholar
  81. 81.
    van den Bent MJ. Can chemotherapy replace radiotherapy in low-grade gliomas? Time for randomized studies. Semin Oncol. 2003;30(6 Suppl 19):39–44.PubMedCrossRefGoogle Scholar
  82. 82.
    Shaw EG, Wang M, Coons S, Brachman D, Buckner JC, Stelzer K, Barger G, Brown PD, Gilbert MR, Mehta MP. Final report of Radiation Therapy Oncology Group (RTOG) protocol 9802: radiation therapy (RT) versus RT  +  procarbazine, CCNU, and vincristine (PCV) chemotherapy for adult low-grade glioma (LGG). 2008 ASCO annual meeting. J Clin Oncol 2008; 26(May 20 suppl):abstr 2006Google Scholar
  83. 83.
    Baumert BG, Stupp R. Is there a place for radiotherapy in low-grade gliomas? Adv Tech Stand Neurosurg. 2010;35:159–82.PubMedCrossRefGoogle Scholar
  84. 84.
    Ruiz J, Lesser GJ. Low-grade gliomas. Curr Treat Options Oncol. 2009;10:231–42.PubMedCrossRefGoogle Scholar
  85. 85.
    Sanson M, Cartalat-Carel S, Taillibert S, Napolitano M, Djafari L, Cougnard J, Gervais H, Laigle F, Carpentier A, Mokhtari K, Taillandier L, Chinot O, Duffau H, Honnorat J, Hoang-Xuan K, Delattre JY, ANOCEF Group. Initial chemotherapy in gliomatosis cerebri. Neurology. 2004;63:270–5.PubMedCrossRefGoogle Scholar
  86. 86.
    Wick W, Platten M, Weller M. New (alternative) temozolomide regimens for the treatment of glioma. Neuro Oncol. 2009;11:69–79.PubMedCrossRefGoogle Scholar
  87. 87.
    Duffau H, Taillandier L, Capelle L. Radical surgery after chemotherapy: a new therapeutic strategy to envision in grade II glioma. J Neurooncol. 2006;80:171–6.PubMedCrossRefGoogle Scholar
  88. 88.
    Spena G, Garbossa D, Barletta L, Prevost C, Versari P. Preoperative chemotherapy for infiltrative low-grade oligoastrocytoma: a useful strategy to maximize surgical resection – case report. Neurol Med Chir (Tokyo). 2010;50:410–3.CrossRefGoogle Scholar
  89. 89.
    Martino J, Taillandier L, Moritz-Gasser S, Gatignol P, Duffau H. Re-operation is a safe and effective therapeutic strategy in recurrent WHO grade II gliomas within eloquent areas. Acta Neurochir (Wien). 2009;151:427–36.CrossRefGoogle Scholar
  90. 90.
    Imani F, Boada FE, Lieberman FS, Davis DK, Deeb EL, Mountz JM. Comparison of proton magnetic resonance spectroscopy with fluorine-18 2-fluoro-deoxyglucose positron emission tomography for assessment of brain tumor progression. J Neuroimaging. 2012;22:184–90.PubMedCrossRefGoogle Scholar
  91. 91.
    Freyschlag CF, Smolczyk DR, Janzen E, Schmieder K, Thomé C, Lohr F, Wenz F, Weiss C, Tuettenberg J, Seiz M. Prolonged administration of temozolomide in adult patients with anaplastic glioma. Anticancer Res. 2011;31:3873–7.PubMedGoogle Scholar
  92. 92.
    Chamberlain MC. Temozolomide: therapeutic limitations in the treatment of adult ­high-grade gliomas. Expert Rev Neurother. 2010;10:1537–44.PubMedCrossRefGoogle Scholar
  93. 93.
    Peyre M, Cartalat-Carel S, Meyronet D, Ricard D, Jouvet A, Pallud J, Mokhtari K, Guyotat J, Jouanneau E, Sunyach MP, Frappaz D, Honnorat J, Ducray F. Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas. Neuro Oncol. 2010;12:1078–82.PubMedCrossRefGoogle Scholar
  94. 94.
    Franceschi E, Omuro AM, Lassman AB, Demopoulos A, Nolan C, Abrey LE. Salvage temozolomide for prior temozolomide responders. Cancer. 2005;104:2473–6.PubMedCrossRefGoogle Scholar
  95. 95.
    Kaloshi G, SierradelRio M, Ducray F, Psimaras D, Idbaih A, Laigle-Donadey F, Taillibert S, Houillier C, Dehais C, Omuro A, Sanson M, Delattre JY, Hoang-Xuan K. Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide. J Neurooncol. 2010;100:439–41.PubMedCrossRefGoogle Scholar
  96. 96.
    Lesser GJ. Chemotherapy of low-grade gliomas. Semin Radiat Oncol. 2001;11:138–44.PubMedCrossRefGoogle Scholar
  97. 97.
    Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent oligodendrogliomas. J Neurooncol. 2002;59:157–63.PubMedCrossRefGoogle Scholar
  98. 98.
    Ius T, Angelini E, Thiebaut de Schotten M, Mandonnet E, Duffau H. Evidence for potentials and limitations of brain plasticity using an atlas of functional resectability of WHO grade II gliomas: towards a “minimal common brain”. Neuroimage. 2011;56:992–1000.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  1. 1.Neurooncology Unit, Department of NeurologyUniversity Hospital, Hospital CentralNancyFrance

Personalised recommendations